Afterward, they examined CML patients treated with nilotinib receiving a gliptin and observed that after gliptin treatment, BCR-ABL1 levels substantially decreased to the point of being undetectable [6]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.